Organisation paid for research Program year 2025 Source: CMS Open Payments

Chevy Chase Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$505,956

164 payments

Through program year 2025, Chevy Chase Clinical Research is reported as receiving $505,956 in research payments, across 164 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$6,458	2
2024	Research	$11,107	9
2023	Research	$15,154	24
2022	Research	$466	18
2021	Research	$114,718	30
2020	Research	$178,219	48
2019	Research	$179,833	33

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $367,989 95 payments
Celgene Corporation $62,567 6 payments
E.R. Squibb & Sons, L.L.C. $55,376 9 payments
Vanda Pharmaceuticals Inc. $9,773 2 payments
Takeda Pharmaceuticals U.S.A., Inc. $9,000 6 payments
Arena Pharmaceuticals, Inc. $1,250 46 payments

Studies the money was for Research payments · program years 2019–2025

M15-991 $88,793 20 payments
M14-431 $72,148 10 payments
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis $45,253 3 payments
M14-430 $40,733 19 payments
PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) (RPC01-3102) $36,921 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies $31,362 4 payments
M14-115 $28,185 3 payments
M16-006 $25,034 4 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 $24,947 10 payments
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease $23,450 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.